New antibody aims to boost immune system against Hard-to-Treat cancers
NCT ID NCT05537740
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 25 times
Summary
This early-phase trial tests a new drug, BAY 3375968, that targets a protein on immune-suppressing cells to help the body fight advanced solid tumors. It is given alone or with another immunotherapy (pembrolizumab) to about 129 adults whose cancers have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Antwerp University Hospital | Oncology Department
Antwerp, 2650, Belgium
-
CHU de Liège
Liège, 4000, Belgium
-
Centre Oscar Lambret - Service Oncologie
Lille, Hauts-de-France, 59000, France
-
Clinica Universidad De Navarra | Madrid | Oncologia
Madrid, 28027, Spain
-
Clinica Universidad De Navarra | Pamplona | Oncologia
Pamplona, Navarre, 31008, Spain
-
Ghent University Hospital | Drug Research Unit Department
Ghent, 9000, Belgium
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510000, China
-
Hospital Universitari Vall D Hebron | Oncologia Medica
Barcelona, 08035, Spain
-
Hospital Universitario Hm Sanchinarro | Oncologia Medica
Madrid, 28050, Spain
-
Institut Bergonie - Unicancer Nouvelle Aquitaine - Service Oncologie medicale
Bordeaux, New Aquitaine, 33000, France
-
Institut Gustave Roussy - Departement d'Innovation Therapeutique et d'Essais Precoces (DITEP)
Villejuif, Île-de-France Region, 94805, France
-
Institut de Cancerologie Ouest - Saint Herblain - Oncologie medicale
Saint-Herblain, Pays de la Loire Region, 44800, France
-
Jilin Cancer Hospital
Changchun, Jilin, 130000, China
-
LinYi Cancer Hospital (Linyi Tumor Hospital)
Linyi, 276001, China
-
National Cancer Center Singapore - Oncology Department
Singapore, 168583, Singapore
-
National University Hospital Medical Centre
Singapore, 119074, Singapore
-
OncoCare Cancer Centre | Gleneagles Medical Centre
Singapore, 258499, Singapore
-
Princess Margaret Cancer Centre - Oncology Department
Toronto, Ontario, M5G 2C4, Canada
-
Royal Marsden NHS Trust (Surrey)
Sutton, Surrey, SM2 5PT, United Kingdom
-
START | San Antonio
San Antonio, Texas, 78229, United States
-
South Texas Accelerated Research Therapeutics | START Rocky Mountain Region
West Valley City, Utah, 84119, United States
-
The Christie NHS Foundation Trust - Christie Hospital
Manchester, Greater Manchester, M204BX, United Kingdom
-
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, 510655, China
-
The University of Chicago Medical Center - Hyde Park - Hematology & Oncology
Chicago, Illinois, 60637, United States
-
UNC Hospitals - UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
-
Universitair Ziekenhuis Leuven | Gasthuisberg Campus - General Medical Oncology
Leuven, 3000, Belgium
Conditions
Explore the condition pages connected to this study.